Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05256225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 16, 2022
Completion date
October 31, 2027
Enrollment
360 (estimated)
Sites
414

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial carcinoma, endometrial clear cell adenocarcinoma, endometrial dedifferentiated carcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed cell adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, uterine corpus malignant mixed mesodermal (mullerian) tumor